Ategenos has officially introduced its investigational SmartPatch platform, following the approval of a key U.S. patent. This advanced system, which has been quietly developed over the past three years, is designed to detect and help address medication non-adherence in patients through wireless technology. The SmartPatch merges drug delivery with cloud-connected features, aiming to improve patient health outcomes and lower healthcare costs related to missed doses.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 15 August 2025
The SmartPatch uses a transdermal patch to deliver reformulated oral solid dose medications, releasing the treatment steadily over several days. It actively tracks whether doses are missed and automatically alerts caregivers so they can take action quickly. This technology is the first to combine passive drug delivery with real-time digital monitoring, targeting the over $500 billion in U.S. healthcare costs linked to patients not following their medication plans.
Don DeGolyer, CEO of Ategenos, said, “We’re adding a new level of intelligence to how medications are used. When patients skip doses, it’s not just money lost—it’s people’s lives being affected through preventable health relapses, hospital visits, and loss of independence. Our SmartPatches allow for early help, giving patients a better chance to stay healthy, at home, and in control of their lives.”
Health Technology Insights: Zynex Names Steven Dyson CEO, Adds New Leadership
The platform offers advanced transdermal drug delivery with long-lasting medication release over multiple days. It features affordable, self-powered disposable electronics that connect wirelessly to Internet-of-Things networks and a secure healthcare cloud. AI-based reminders help caregivers know when doses are missed, supporting timely actions that could prevent hospital stays. The patch is easy to apply like any other transdermal patch, requiring no special handling, and offers direct, real-time tracking of medication use in community settings.
Ategenos is developing a range of proprietary drugs through the FDA’s 505(b)(2) regulatory pathway, focusing on treatments for behavioral health, cardiovascular, central nervous system, and oncology conditions. The company is also exploring partnerships with pharmaceutical companies for three major opportunities: extending the life of drugs as they near the end of their patent period, reformulating compounds where patient compliance is a problem, and creating connected real-time alternatives to traditional oral solid dose medications that struggle with adherence issues. Ategenos is working closely with a select group of pharmaceutical partners, aiming to lead in connected therapeutic solutions and leaving a few strategic partnership opportunities open for those who want to be early adopters of this scalable platform. The company is also reaching out to potential investors and strategic collaborators who share the goal of solving the global problem of medication non-adherence.
Health Technology Insights: Tivic Health Advances Entolimod Talks at MHSRS 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
